The Claim
In obese diabetic ob/ob mice, daily administration of GIP(3-42) or GLP-1(9-36)amide for 14 days resulted in no change in pancreatic insulin content, islet number, or islet morphology.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese diabetic mice, daily injections of GIP(3-42) or GLP-1(9-36)amide for 14 days did not alter the amount of insulin in the pancreas, the number of islets, or their structure.
See the scientific wording
In obese diabetic ob/ob mice, 14 days of daily GIP(3-42) or GLP-1(9-36)amide administration had no effect on pancreatic insulin content, islet number, or islet morphology, indicating no structural impact on beta-cell mass.
These hormone fragments improve how muscle, liver, and fat tissues respond to insulin, allowing the body to lower blood sugar without needing more insulin or changing the pancreas. The insulin-producing cells in the pancreas stay the same size, number, and shape because these fragments do not act on the pancreas at all.
What the research says
1 studyIn diabetic mice, two weeks of daily injections of these two hormone fragments didn’t change the size, number, or shape of the insulin-producing cells in the pancreas — so they didn’t make the pancreas grow or shrink in any way.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.